IDEXX Laboratories (NASDAQ:IDXX) Cut to Hold at Wall Street Zen

IDEXX Laboratories (NASDAQ:IDXX) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Sunday.

Other research analysts also recently issued reports about the company. Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective for the company. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. UBS Group lowered their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, June 25th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

IDXX stock traded up $4.97 during trading on Friday, hitting $563.57. The stock had a trading volume of 612,524 shares, compared to its average volume of 657,640. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories has a twelve month low of $506.91 and a twelve month high of $769.98. The stock has a market capitalization of $44.45 billion, a P/E ratio of 41.50, a PEG ratio of 3.08 and a beta of 1.55. The company’s 50-day moving average price is $555.09 and its two-hundred day moving average price is $604.44.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts predict that IDEXX Laboratories will post 14.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth about $3,666,459,000. J. Stern & Co. LLP grew its position in IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after acquiring an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after purchasing an additional 1,442,174 shares during the period. Wellington Management Group LLP increased its stake in IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after purchasing an additional 592,834 shares during the period. Finally, Norges Bank acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth about $332,265,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.